Antisense oligonucleotides (ASOs) are powerful therapeutic tools that bind to specific RNA target sequences through complementary base pairing, leading to RNA degradation, changes in RNA splicing, translation inhibition, or disruption of RNA‐protein interactions.[32] Therefore, we designed and synthesized a series of 2′‐Omethoxyethy‐modified ASOs to inhibit ΔIL‐18 production in tumor cells by blocking the splicing site of IL‐18 (Figure 3I). This evidence concerns the gene IL18 and neoplasm.